NO20044049L - Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner - Google Patents

Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner

Info

Publication number
NO20044049L
NO20044049L NO20044049A NO20044049A NO20044049L NO 20044049 L NO20044049 L NO 20044049L NO 20044049 A NO20044049 A NO 20044049A NO 20044049 A NO20044049 A NO 20044049A NO 20044049 L NO20044049 L NO 20044049L
Authority
NO
Norway
Prior art keywords
propanediaminesulfamic
pyridyl
synthesis
preparation
acid
Prior art date
Application number
NO20044049A
Other languages
English (en)
Norwegian (no)
Inventor
Gregg Brian Feigelson
Joseph Zeldis
Anita Wai-Yin Chan
Ivo Jirkovsky
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20044049L publication Critical patent/NO20044049L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20044049A 2002-03-12 2004-09-24 Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner NO20044049L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36345702P 2002-03-12 2002-03-12
PCT/US2003/007228 WO2003078396A1 (en) 2002-03-12 2003-03-10 Preparation of n1-(2’-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines

Publications (1)

Publication Number Publication Date
NO20044049L true NO20044049L (no) 2004-09-24

Family

ID=28041771

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044049A NO20044049L (no) 2002-03-12 2004-09-24 Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner

Country Status (27)

Country Link
US (1) US6784294B2 (zh)
EP (2) EP1483243B1 (zh)
JP (1) JP4397693B2 (zh)
KR (1) KR20040091720A (zh)
CN (1) CN100341854C (zh)
AR (1) AR038932A1 (zh)
AT (2) ATE449073T1 (zh)
AU (1) AU2003220122A1 (zh)
BR (1) BR0308315A (zh)
CA (1) CA2477886A1 (zh)
CY (1) CY1106677T1 (zh)
DE (2) DE60330199D1 (zh)
DK (1) DK1483243T3 (zh)
EC (1) ECSP045291A (zh)
ES (2) ES2334836T3 (zh)
HK (1) HK1068618A1 (zh)
IL (1) IL163829A0 (zh)
MX (1) MXPA04008731A (zh)
NO (1) NO20044049L (zh)
NZ (1) NZ535170A (zh)
PT (1) PT1483243E (zh)
RU (1) RU2314294C2 (zh)
SI (1) SI1483243T1 (zh)
TW (1) TWI288642B (zh)
UA (1) UA80272C2 (zh)
WO (1) WO2003078396A1 (zh)
ZA (1) ZA200408213B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223824A1 (en) * 2000-11-28 2006-10-05 Wyeth Serotonergic agents
CA2453837C (en) * 2001-07-20 2011-10-04 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder using eltoprazine and related compounds
JP4397693B2 (ja) 2002-03-12 2010-01-13 ワイス N1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用
US7361773B2 (en) * 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
WO2003078420A2 (en) * 2002-03-12 2003-09-25 Wyeth Process for making chiral 1,4-disubstituted piperazines
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
PA8626301A1 (es) * 2004-03-19 2006-12-07 Wyeth Wyeth Proceso para preparar derivados de n-aril-piperazina
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
AU2006218845A1 (en) * 2005-03-01 2006-09-08 Wyeth Crystalline and amorphous 4-cyano-N{(2R)-2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl)-piperazin-1-yl)-propyl}-N-pyridin-2-yl-benzamide hydrochloride
AU2011225122B8 (en) * 2010-03-12 2013-12-12 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
GB201310126D0 (en) * 2013-06-06 2013-07-24 Univ Leicester Novel pyrrole derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586794T2 (de) 1984-12-21 1993-05-27 Duphar Int Res Arzneimittel mit psychotroper wirkung.
JPH01125357A (ja) 1987-11-06 1989-05-17 Dainippon Pharmaceut Co Ltd トリペプチドの誘導体
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
JP3077047B2 (ja) 1993-04-16 2000-08-14 参天製薬株式会社 新規ピペラジン誘導体
EP0763024B1 (en) * 1994-06-03 2002-08-14 JOHN WYETH & BROTHER LIMITED Processes and intermediates for the preparation of piperazine derivatives
GB9411099D0 (en) 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
GB9514901D0 (en) * 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
CA2251017A1 (en) 1996-04-10 1997-10-16 Mark E. Duggan .alpha.v.beta.3 antagonists
MXPA04008729A (es) * 2002-03-12 2005-07-13 Wyeth Corp Proceso para sintetizacion de piperazinas n-arilicas quirales.
JP4397693B2 (ja) 2002-03-12 2010-01-13 ワイス N1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用

Also Published As

Publication number Publication date
UA80272C2 (en) 2007-09-10
WO2003078396A8 (en) 2004-01-29
CN100341854C (zh) 2007-10-10
DE60330199D1 (de) 2009-12-31
CN1642916A (zh) 2005-07-20
DK1483243T3 (da) 2007-08-06
US20030204087A1 (en) 2003-10-30
RU2314294C2 (ru) 2008-01-10
ATE449073T1 (de) 2009-12-15
JP4397693B2 (ja) 2010-01-13
TWI288642B (en) 2007-10-21
CY1106677T1 (el) 2012-05-23
EP1801103A1 (en) 2007-06-27
MXPA04008731A (es) 2004-12-06
JP2005526088A (ja) 2005-09-02
AR038932A1 (es) 2005-02-02
CA2477886A1 (en) 2003-09-25
ATE360002T1 (de) 2007-05-15
WO2003078396A1 (en) 2003-09-25
ZA200408213B (en) 2007-03-28
AU2003220122A1 (en) 2003-09-29
SI1483243T1 (sl) 2007-08-31
NZ535170A (en) 2006-03-31
ES2334836T3 (es) 2010-03-16
DE60313301T2 (de) 2007-12-27
ES2283762T3 (es) 2007-11-01
KR20040091720A (ko) 2004-10-28
ECSP045291A (es) 2004-10-26
DE60313301D1 (de) 2007-05-31
IL163829A0 (en) 2005-12-18
EP1483243B1 (en) 2007-04-18
BR0308315A (pt) 2004-12-28
US6784294B2 (en) 2004-08-31
EP1483243A1 (en) 2004-12-08
RU2004130314A (ru) 2005-04-10
HK1068618A1 (en) 2005-04-29
PT1483243E (pt) 2007-06-27
EP1801103B1 (en) 2009-11-18
TW200303751A (en) 2003-09-16

Similar Documents

Publication Publication Date Title
ATE296302T1 (de) 4-(1,3,4-thiadiazolyl-2-yl)-1,4-diazabizyklo- 3.2.2 nonanderivate, ihre herstellung und ihre therapeutische verwendung
HK1068618A1 (en) Preparation of n1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
NO20031407L (no) Glukopyranosyloksybenzylbenzen-derivater og medisinske sammensetninger inneholdende det samme
ATE284886T1 (de) Benzimidazolderivate, ihre herstellung und therapeutische verwendung
DE602004022946D1 (de) 4-cyanopyrazol-3-carbonsäureamidderivate, herstellung und therapeutische anwendung davon
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
EE200300545A (et) 4-(fenüülpiperasinüülmetüül)bensamiidi derivaadid, nende valmistamine ja kasutamine valu, ärevuse ja seedetrakti häirete ravis
DK1267880T3 (da) Entecavir-formulering med lav dosis og anvendelse deraf
DE60209486D1 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
ATE267201T1 (de) 4-(2-phenylthiazol-5-yl)1,4- diazabicyclo(3.2.2)nonanederivate, ihre herstellung und therapeutische verwendung
DE60013021D1 (de) Herstellung von S,S und R,S Aminosäuren-Isosteren
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DE60208044D1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
IS6378A (is) Efnasambönd og samsetningar gegn dvergveirum, notkun þeirra til lyfjagerðar og efni til að framleiða þau
DE50114889D1 (de) Lithium-komplexe von n-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecan, deren herstellung und verwendung
DK1202996T3 (da) Titanforbindelser, fremstilling og anvendelse heraf
DE60204755D1 (de) "3,7-diazabicyclo(3.3.0)octane und deren verwendung bei der behandlung von herzrhythmusstörungen"
PL367676A1 (en) Novel heterocyclic derivatives and medicinal use thereof
NO20043295L (no) Faste salt-benzazepinforbindelser og deres anvendelse ved fremstilling av farmasoytiske forbindelser
DE60217870D1 (de) Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application